By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is that Omega Fund Management's sale of ALMS shares is likely a rebalancing act rather than a loss of conviction. However, there's significant concern about the stock's valuation, execution risks, and competition in the TYK2 inhibitor space.
Risk: The stock's high valuation and thin float make it vulnerable to price corrections if institutional holders continue trimming their positions, and the crowded autoimmune market poses challenges for commercial differentiation.
Opportunity: The company's strong cash position and late-stage pipeline present opportunities for potential licensing or strategic deals that could influence dilution and clinical upside.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
Omega Fund Management sold 411,968 shares of Alumis; the estimated trade value is $10.3 million (based on quarterly average price).
The quarter-end position value decreased by $1.06 million, reflecting both trading activity and price changes.
The transaction represented 6.3% of Omega Fund Management's 13F reportable assets under management (AUM).
After the sale, Omega holds 241,255 Alumis shares valued at $5.31 million.
On May 15, 2026, Omega Fund Management disclosed in an SEC filing that it sold 411,968 shares of Alumis (NASDAQ:ALMS), with the estimated transaction value at $10.3 million based on quarterly average pricing.
According to its SEC filing dated May 15, 2026, Omega Fund Management reduced its position in Alumis by 411,968 shares during the first quarter. The estimated transaction value, based on the period’s average closing price, was $10.3 million. The fund’s stake at quarter-end stood at 241,255 shares, with the position’s value decreasing by $1.06 million compared to the prior quarter, a figure reflecting both sale activity and market price movement.
NASDAQ: BBNX: $13.19 million (8.1% of AUM)
As of Friday, Alumis shares were priced at $22.87, up 327% over the past year and well outperforming the S&P 500’s roughly 25% gain in the same period.
| Metric | Value | |---|---| | Revenue (TTM) | $24.05 million | | Net income (TTM) | ($243.33 million) | | Market capitalization | $2.9 billion | | Price (as of Friday) | $22.87 |
Alumis is positioned in the biotechnology sector, leveraging expertise in allosteric TYK2 inhibition to address complex immune-mediated conditions. Its research and development pipeline targets significant opportunities in autoimmune and neuroinflammatory disease treatment.
This sale ultimately looks more like profit-taking after an enormous rally than a full-blown loss of conviction. Even after trimming the position again, Omega still kept Alumis as a meaningful holding in a biotech-heavy portfolio, suggesting the firm may simply be managing exposure after the stock’s more than 300% run over the past year.
The bigger story for long-term investors is whether Alumis can turn promising clinical momentum into an actual commercial franchise. The company on Thursday reported late-stage psoriasis data showing PASI 90 response rates above 60% and PASI 100 responses topping 40% by Week 24 for envudeucitinib, its lead TYK2 inhibitor candidate. Management said plans remain on track for an FDA submission in the fourth quarter, while potentially pivotal lupus data is expected later this year.
Financially, Alumis ended the quarter with $569.5 million in cash and marketable securities, which management says should fund operations into late 2027. And looking at the bottom line, the company still posted a steep quarterly net loss of $93.1 million as research spending remained elevated.
Ultimately, the opportunity now hinges less on hype around TYK2 drugs and more on execution, especially whether Alumis can differentiate itself in an increasingly crowded autoimmune treatment market.
Before you buy stock in Alumis, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Alumis wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $468,861! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,445,212!
Now, it’s worth noting Stock Advisor’s total average return is 1,013% — a market-crushing outperformance compared to 210% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of May 15, 2026. *
Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Alumis's current valuation reflects priced-in perfection, leaving minimal margin for error in the upcoming FDA submission process."
The market is fixating on Omega Fund Management’s profit-taking as a signal, but the real story is the $2.9 billion valuation against a $243 million TTM net loss. With a 327% rally, Alumis is priced for perfection in the TYK2 inhibitor space. While the PASI 90/100 data for envudeucitinib is impressive, the autoimmune market is becoming a crowded trade dominated by incumbents with deeper pockets. Omega’s 6.3% portfolio reduction suggests they are rebalancing risk, not necessarily exiting, but retail investors should be wary. At current levels, the risk-to-reward ratio is skewed heavily toward the downside if the FDA submission faces any regulatory friction or if commercial differentiation proves elusive.
The strong PASI response rates could signal a 'best-in-class' profile that justifies a premium valuation, potentially making Alumis an attractive M&A target for a large-cap pharmaceutical firm looking to bolster its immunology pipeline.
"N/A"
[Unavailable]
"A 327% rally on Phase 2b data in a crowded TYK2 space, combined with a major holder trimming 6.3% of AUM, suggests valuation has outpaced clinical and commercial risk—not that conviction is intact."
Omega's 6.3% AUM sale is being framed as profit-taking, but the real signal is portfolio rebalancing away from a $2.9B market-cap biotech with $24M TTM revenue and -$243M net income. Yes, ALMS is up 327%, but that's precisely when rational allocators trim. The cash runway to late 2027 is real, but the clinical data (PASI 90 >60%, PASI 100 >40%) is Phase 2b—not Phase 3. TYK2 is crowded (Pfizer, GSK, others). Omega kept 241k shares (3.3% of AUM), suggesting measured conviction, not panic. But the article conflates 'not selling everything' with 'still bullish.' That's a low bar.
Omega may simply be harvesting gains to fund higher-conviction bets (BCAX 29.2%, NUVB 21.2% of AUM are their real portfolio), and Alumis's Q4 FDA submission + late-year lupus data could re-rate the stock 50%+ if efficacy holds, making this sale look premature in 12 months.
"ALMS's upside hinges on delivering durable late-stage data and a successful FDA path; without that, the current premium is at risk."
Omega’s sale of 411,968 ALMS shares looks like routine rebalancing, not a wholesale loss of conviction. The stock’s 327% YoY surge has priced in a strong TYK2 momentum thesis, including envudeucitinib data and an FDA filing later in 2026. Yet Alumis remains cash-rich but unprofitable, burning cash as it advances a late-stage psoriasis/lupus program. Execution risk, data durability, and regulatory timing remain binary catalysts. The article glosses over safety signals, payer dynamics, and potential dilution, and omits how competitive TYK2s are evolving. Missing context: trial readouts, real-world durability, and the likelihood of licensing or strategic deals that would influence dilution and clinical upside.
Omega’s 6.3% AUM cut could reflect prudent risk-off or portfolio rebalancing rather than a bearish view on Alumis; a biotechnology-heavy fund often trims during volatility, not because the thesis is dead.
"The stock's thin liquidity makes even modest institutional trimming a disproportionate catalyst for a sharp downward price correction."
Claude and ChatGPT are missing the liquidity trap. Omega isn't just rebalancing; they are managing a massive position in a thin-float stock. With ALMS up 327%, retail volume is likely exhausted. If institutional holders like Omega continue systematic trimming, the stock lacks the depth to absorb the supply without a significant price correction. The 'best-in-class' narrative ignores that TYK2 inhibitors face a brutal commercial reality: payers prioritize cost-effectiveness over marginal PASI improvements in a crowded, commoditized market.
[Unavailable]
"Thin-float selling pressure can crater the stock price without threatening the company's survival or clinical timeline."
Gemini's liquidity trap argument is sharp, but it conflates two separate risks. Thin float + systematic selling = price pressure, yes. But ALMS has $600M+ cash and no debt maturity until 2027—the company survives regardless of stock price. The real risk isn't a liquidity crisis; it's retail capitulation triggering a cascade that makes future capital raises dilutive. That's a valuation problem, not an existential one. Omega's trim matters tactically, not strategically.
"The real risk sits in dilution and financing hurdles long before a liquidity crunch, even with a thin float."
Gemini, the liquidity-trap angle is seductive but incomplete. Even with a thin float, ALMS' $600M+ cash and a multi-year runway to late 2027 undercuts a pure liquidity crisis—dilutive equity raises and a potential funding hurdle remain the bigger, longer-term risk. The real test is whether the TYK2 story can sustain a $2.9B market cap in a crowded, payer-conscious market, not whether Omega trims once. Beware the dilution tail risk.
The panel consensus is that Omega Fund Management's sale of ALMS shares is likely a rebalancing act rather than a loss of conviction. However, there's significant concern about the stock's valuation, execution risks, and competition in the TYK2 inhibitor space.
The company's strong cash position and late-stage pipeline present opportunities for potential licensing or strategic deals that could influence dilution and clinical upside.
The stock's high valuation and thin float make it vulnerable to price corrections if institutional holders continue trimming their positions, and the crowded autoimmune market poses challenges for commercial differentiation.